Search the Newsreel

Dynatrace (DT) Could Be 47% Below Fair Value Following Its August 5 Earnings Date

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Dynatrace (DT) is in focus after scheduling the release of its first quarter fiscal 2027 results for August 5, 2026, with investors watching how fresh numbers might …

Avoiding Lag: Real-Time Signals in (ATRA) Movement

This article provides a real-time analysis of Atara Biotherapeutics Inc. (NASDAQ: ATRA) stock movement, highlighting weak sentiment across all horizons supporting a short bias. It details three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. …

Globeflex Capital L P Purchases 104,163 Shares of Dynatrace, Inc. $DT

Globeflex Capital L P significantly increased its stake in Dynatrace, Inc. (NYSE:DT) by 391.1% in the first quarter, adding 104,163 shares to own a total of 130,797 shares valued at $4.84 million. Other major institutions also expanded their holdings, with institutional investors now owning …

Dynatrace, Inc. (DT) stock price, news, quote and history

This article provides a comprehensive overview of Dynatrace, Inc. (DT) stock, including its current price, historical data, and key financial metrics. It details the company's business activities as an AI-powered observability platform and presents analyst insights, performance comparisons with competitors, and earnings trends. The …

Price to sales forward of Atara Biotherapeutics, Inc. – NASDAQ:ATRA

This article provides the "Price to sales forward" financial metric for Atara Biotherapeutics, Inc. (NASDAQ: ATRA). It is a finance-related data point from TradingView, which aggregates market data from sources like ICE Data Services and FactSet. The page indicates no current trade activity for …

Atara Biotherapeutics (NASDAQ:ATRA) Share Price Passes Below 50-Day Moving Average - Should You Sell?

Price to book forward of Atara Biotherapeutics Inc – SWB:AT20

This article provides financial data for Atara Biotherapeutics Inc (SWB:AT20) on the Stuttgart Stock Exchange, specifically focusing on its price to book forward ratio. It highlights that the market is currently closed with no trades. The content is primarily a data presentation with minimal …

Enterprise value to revenue forward of Atara Biotherapeutics Inc – SWB:AT20

This article provides financial information for Atara Biotherapeutics Inc (SWB:AT20), specifically focusing on its enterprise value to revenue forward. It notes that the market for AT20 was closed with no trades. The content also mentions that financial data is provided by ICE Data Services …

DYNATRACE, INC : TD COWEN RAISES TARGET PRICE TO $50 FROM $45

TD Cowen has increased its target price for Dynatrace, Inc. stock from $45 to $50. This adjustment by the financial services firm indicates a more optimistic outlook on the company's future performance.

Dynatrace Schedules Aug. 5 Call to Discuss Quarterly Results

Dynatrace (NYSE: DT) announced it will report its first-quarter fiscal year 2027 financial results on August 5, 2026, before U.S. financial markets open. The company will host a conference call and live webcast at 8:00 a.m. Eastern Time to discuss these results and its …

Dynatrace to Report First Quarter Fiscal Year 2027 Financial Results

BOSTON, July 22, 2026--(BUSINESS WIRE)--Dynatrace (NYSE: DT), the leading AI-powered observability platform, today announced that it will report financial results for its first quarter of fiscal year 2027 ended June 30, 2026 before the U.S. financial markets open on August 5, 2026. In conjunction …

Bank of New York Mellon Corp Sells 101,543 Shares of Dynatrace, Inc. $DT

Bank of New York Mellon Corp decreased its stake in Dynatrace, Inc. by 4.3% in the first quarter, selling over 101,000 shares but still retaining a significant holding valued at about $82.8 million. This comes as Dynatrace reported stronger-than-expected quarterly earnings and revenue growth. …

Dynatrace (DT) Stock Drops Despite Market Gains: Important Facts to Note

Dynatrace (DT) shares dropped by 4.16% despite overall market gains, closing at $42.85. The company showed a 10.5% gain over the previous month, outperforming its sector. Upcoming earnings predict a 7.14% EPS growth and 15.07% revenue increase.

Dynatrace slides as software peers weaken and no fresh company catalyst emerges

Dynatrace (DT) shares dropped 4.7% due to broad weakness in the software sector and profit-taking, rather than any new negative company announcement. Peer companies in cloud and observability software also traded lower, and Dynatrace's most recent financial update in May showed positive growth expectations …

Dynatrace Is Maintained at Buy by Jefferies

Jefferies has reiterated its Buy rating on Dynatrace (NYSE:DT). This decision was based on a comprehensive analysis, which suggests a positive outlook for the company's stock.

DYNATRACE, INC. : OPPENHEIMER RAISES TARGET PRICE TO $55 FROM $45

Oppenheimer has increased its target price for Dynatrace, Inc. (DT.N) to $55 from $45. This adjustment indicates a more optimistic outlook by the firm on Dynatrace's future stock performance. The report was published by Reuters through Bitget News.

Dynatrace Seen Building Toward Long-Term Financial Targets, Oppenheimer Says

Oppenheimer analysts believe Dynatrace is making progress towards its long-term financial goals, citing positive trends in its business. The report highlights the company's strong performance and strategic initiatives that are expected to contribute to future growth. This optimistic outlook suggests that Dynatrace is well-positioned …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) securities. The investigation focuses on whether Atara and its officers engaged in corporate wrongdoing, particularly for investors who bought shares before May 20, 2024, and still …

(DT) and the Role of Price-Sensitive Allocations

This article analyzes Dynatrace Inc. (NYSE: DT), highlighting strong near and mid-term sentiment despite a weak long-term outlook. It identifies no resistance levels above the current price, suggesting compelling upside potential. The report provides three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored …

Dynatrace (NYSE: DT) CAO vests 1,323 RSUs; now holds 35,457 shares

Dynatrace's SVP and Chief Accounting Officer, Daniel S. Yates, reported the vesting of 1,323 Restricted Stock Units (RSUs) on July 15, 2026. After withholding 389 shares for tax obligations at $45.17 per share, Yates now directly holds 35,457 common shares and has 6,612 RSUs …

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Atara Biotherapeutics, Inc. (NASDAQ: ATRA) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Atara securities prior to May 20, 2024, and still hold them, to contact …

Dynatrace Is Maintained at Overweight by Keybanc

Keybanc has reiterated its Overweight rating on Dynatrace (DT). The price target for Dynatrace was also maintained at $65.00 by Keybanc.

DT Maintained by Keybanc -- Price Target Raised to $53.00

Keybanc has reiterated an "Overweight" rating for Dynatrace (DT) and increased its price target from $47.00 to $53.00, reflecting a positive outlook on the company's growth potential. Dynatrace is currently considered significantly undervalued according to GF Value™, with a GF Score™ of 85/100, indicating …

Datadog, Dynatrace, Rubrik, Snowflake see price target increases at KeyBanc (DDOG:NASDAQ)

KeyBanc Capital Markets increased price targets for Datadog, Dynatrace, Rubrik, and Snowflake ahead of their upcoming earnings reports. Datadog's target rose to $320 from $225, and Dynatrace's increased to $53 from $47.

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities. The investigation focuses on whether Atara and its officers engaged in corporate wrongdoing, particularly for investors who purchased shares before May 20, 2024. The …

RBC Raises Price Target on Dynatrace to $50 From $45, Keeps Outperform Rating

RBC Capital Markets has increased its price target for Dynatrace (NYSE: DT) shares to $50, up from the previous $45, while maintaining an Outperform rating on the stock. This adjustment reflects continued analyst confidence in the AI-powered observability platform company.

Dynatrace Named a Leader in the 2026 Gartner® Magic Quadrant™ for Observability Platforms for the 16th Time

Dynatrace has been recognized as a Leader in the 2026 Gartner Magic Quadrant for Observability Platforms for the 16th time. The company was evaluated among 19 vendors and acknowledged for its completeness of vision and ability to execute. Dynatrace emphasizes its AI-powered platform provides …

DA Davidson raises Dynatrace stock price target on AI tailwinds

DA Davidson has increased its price target for Dynatrace (NYSE:DT) shares from $45.00 to $60.00, reiterating a Buy rating, citing strong AI tailwinds and the company's comprehensive platform. This new target is consistent with InvestingPro's Fair Value, suggesting the stock is currently undervalued. Despite …

Yatra Online shares rise 5.5% as CNBC-Awaaz report says Ixigo may buy 15-20% stake

Yatra Online gains on report of potential stake sale to Ixigo; BSE seeks clarification

Yatra Online shares jump 6%, up 30% YoY; what’s fueling the travel firm’s rally on Friday?

Asia Consolidated DMC declares no encumbrance on Yatra Online shares in FY26

TBO Tek, Le Travenues, Yatra Online shares surge up to 10%; here's why

Yatra Online Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Earnings call transcript: Yatra Online Q4 2026 misses revenue, stock rises

Yatra Online Q4 revenue drops 26 pc, EBITDA falls sharply